The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications Pub Date : 2024-05-31 DOI:10.1016/j.jdiacomp.2024.108781

Evangelos C. Rizos , Christos F. Tagkas , Alexandros-Georgios I. Asimakopoulos , Vasileios Tsimihodimos , Georgia Anastasiou , Manfredi Rizzo , Aris P. Agouridis , Evangelia E. Ntzani

{"title":"The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials","authors":"Evangelos C. Rizos , Christos F. Tagkas , Alexandros-Georgios I. Asimakopoulos , Vasileios Tsimihodimos , Georgia Anastasiou , Manfredi Rizzo , Aris P. Agouridis , Evangelia E. Ntzani","doi":"10.1016/j.jdiacomp.2024.108781","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to assess arterial stiffness. We evaluated the effect of sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) on arterial stiffness indices.</p></div><div><h3>Methods</h3><p>We searched PubMed (up to January 2024) for RCTs assessing the effect of SGLT2i or GLP1-RA on arterial stiffness with reporting outcomes PWV and AIx. Effect sizes of the included studies were expressed as weighted mean difference (WMD) and 95 % confidence interval. Subgroup analyses were performed based on comparator (placebo vs. active comparator), design (RCT vs. crossover), population (diabetic vs. all) and blindness (yes vs. no).</p></div><div><h3>Results</h3><p>A total of 19 studies (SGLT2i, 12 studies; GLP1-RA, 5 studies; SGLT2i/GLP1-RA combination, 2 studies) assessing 1212 participants were included. We did not find any statistically significant association between GLP1-RA or SGLT2i and PWV or AIx. None of the subgroup analyses showed any statistically significant result.</p></div><div><h3>Conclusion</h3><p>No evidence of a favorable change in arterial stiffness indices (PWV, AIx) was found following the administration of SGLT2i or GLP1-RA.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 7","pages":"Article 108781"},"PeriodicalIF":2.9000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and its complications","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1056872724001077","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to assess arterial stiffness. We evaluated the effect of sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) on arterial stiffness indices.

Methods

We searched PubMed (up to January 2024) for RCTs assessing the effect of SGLT2i or GLP1-RA on arterial stiffness with reporting outcomes PWV and AIx. Effect sizes of the included studies were expressed as weighted mean difference (WMD) and 95 % confidence interval. Subgroup analyses were performed based on comparator (placebo vs. active comparator), design (RCT vs. crossover), population (diabetic vs. all) and blindness (yes vs. no).

Results

A total of 19 studies (SGLT2i, 12 studies; GLP1-RA, 5 studies; SGLT2i/GLP1-RA combination, 2 studies) assessing 1212 participants were included. We did not find any statistically significant association between GLP1-RA or SGLT2i and PWV or AIx. None of the subgroup analyses showed any statistically significant result.

Conclusion

No evidence of a favorable change in arterial stiffness indices (PWV, AIx) was found following the administration of SGLT2i or GLP1-RA.

查看原文本刊更多论文

SGLT2 抑制剂和 GLP1 受体激动剂对动脉僵化的影响：随机对照试验荟萃分析

背景脉搏波速度（PWV）和增强指数（AIx）是用于评估动脉僵化的指数。我们评估了钠葡萄糖协同转运体-2抑制剂（SGLT2i）和胰高血糖素样肽-1受体激动剂（GLP1-RA）对动脉僵化指数的影响。方法我们在PubMed（截至2024年1月）上检索了评估SGLT2i或GLP1-RA对动脉僵化影响的RCT，并报告了脉搏波速度和增强指数。纳入研究的效应大小以加权平均差 (WMD) 和 95 % 置信区间表示。根据比较对象（安慰剂与活性比较对象）、设计（RCT 与交叉研究）、人群（糖尿病患者与所有患者）和失明情况（是与否）进行了亚组分析。结果共纳入了 19 项研究（SGLT2i，12 项研究；GLP1-RA，5 项研究；SGLT2i/GLP1-RA 联合用药，2 项研究），评估了 1212 名参与者。我们没有发现 GLP1-RA 或 SGLT2i 与脉搏波速度或 AIx 之间有任何统计学意义上的关联。结论没有证据表明服用 SGLT2i 或 GLP1-RA 后动脉僵化指数（脉搏波速度、动脉僵化指数）会发生有利的变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of diabetes and its complications 医学-内分泌学与代谢

CiteScore

5.90

自引率

3.30%

发文量

153

审稿时长

16 days

期刊介绍： Journal of Diabetes and Its Complications (JDC) is a journal for health care practitioners and researchers, that publishes original research about the pathogenesis, diagnosis and management of diabetes mellitus and its complications. JDC also publishes articles on physiological and molecular aspects of glucose homeostasis. The primary purpose of JDC is to act as a source of information usable by diabetes practitioners and researchers to increase their knowledge about mechanisms of diabetes and complications development, and promote better management of people with diabetes who are at risk for those complications. Manuscripts submitted to JDC can report any aspect of basic, translational or clinical research as well as epidemiology. Topics can range broadly from early prediabetes to late-stage complicated diabetes. Topics relevant to basic/translational reports include pancreatic islet dysfunction and insulin resistance, altered adipose tissue function in diabetes, altered neuronal control of glucose homeostasis and mechanisms of drug action. Topics relevant to diabetic complications include diabetic retinopathy, neuropathy and nephropathy; peripheral vascular disease and coronary heart disease; gastrointestinal disorders, renal failure and impotence; and hypertension and hyperlipidemia.